Metcalfe S, Wheeler T K, Picken S, Negus S
University of Cambridge, Department of Surgery, Addenbrookes Hospital, Cambridge, UK.
Breast Cancer Res. 2000;2(6):438-43. doi: 10.1186/bcr91. Epub 2000 Aug 21.
Serial plasma samples from 1006 patients with breast cancer revealed: (i) no correlation of p53 autoantibody status with disease status at the time of sample collection, or with menopausal status at time of primary diagnosis of breast cancer; (ii) 155 out of 1006 (15%) of patients were positive for p53 autoantibodies, and these patients tended to have a persistent autoantibody status throughout follow up, irrespective of disease behaviour; and (iii) where a negative autoantibody status was found at primary diagnosis of breast cancer, this negative status persisted throughout follow up, irrespective of later disease behaviour. We conclude that screening for p53 autoantibody status is not informative on residual tumour activity nor on therapeutic responsiveness.
对1006例乳腺癌患者的系列血浆样本检测发现：（i）p53自身抗体状态与样本采集时的疾病状态，或与乳腺癌初诊时的绝经状态均无相关性；（ii）1006例患者中有155例（15%）p53自身抗体呈阳性，这些患者在整个随访过程中倾向于保持自身抗体状态，与疾病行为无关；（iii）在乳腺癌初诊时发现自身抗体状态为阴性的患者，无论后期疾病行为如何，该阴性状态在整个随访过程中均持续存在。我们得出结论，筛查p53自身抗体状态对于残余肿瘤活性或治疗反应性并无指导意义。
